Article
Oncology
Helen Sadik, Daryl Pritchard, Derry-Mae Keeling, Frank Policht, Peter Riccelli, Gretta Stone, Kira Finkel, Jeff Schreier, Susanne Munksted
Summary: Many patients with cancer are unable to receive the most effective personalized treatments due to challenges in integrating predictive biomarker testing into clinical care. Clinical practice gaps, such as operational inefficiencies and inappropriate testing result usage, contribute to the loss of patients along the precision oncology pathway. This study analyzed the impact of these gaps on the treatment of advanced non-small-cell lung cancer (aNSCLC), revealing that a significant percentage of eligible patients do not benefit from precision oncology therapies.
JCO PRECISION ONCOLOGY
(2022)
Article
Medicine, Research & Experimental
Dan Yan, Justus M. Huelse, Dmitri Kireev, Zikang Tan, Luxiao Chen, Subir Goyal, Xiaodong Wang, Stephen Frye, Madhusmita Behera, Frank Schneider, Suresh S. Ramalingam, Taofeek Owonikoko, H. Shelton Earp, Deborah DeRyckere, Douglas K. Graham
Summary: Acquired resistance is inevitable in non-small cell lung cancers (NSCLCs) treated with osimertinib (OSI). Activation of MERTK is associated with OSI resistance and inhibition of MERTK kinase can resensitize resistant cells to OSI.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
Article
Oncology
Mei Elsayed, Farastuk Bozorgmehr, Daniel Kazdal, Anna-Lena Volckmar, Holger Sueltmann, Jurgen R. Fischer, Mark Kriegsmann, Albrecht Stenzinger, Michael Thomas, Petros Christopoulos
Summary: The study retrospectively analyzed the treatment flow of 145 ALK(+) NSCLC patients receiving TKI therapy, finding that approximately 25-30% of patients forego subsequent systemic therapy due to rapid clinical deterioration. Most patients died under the first failing therapy, indicating the need for closer patient monitoring and broader profiling to support earlier and better directed use of available therapies.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Laura Q. M. Chow, Fabrice Barlesi, Erin M. Bertino, Martin J. van den Bent, Heather A. Wakelee, Patrick Y. Wen, Chao-Hua Chiu, Sergey Orlov, Rita Chiari, Margarita Majem, Mark McKeage, Chong-Jen Yu, Pilar Garrido, Felipe K. Hurtado, Pilar Cazorla Arratia, Yuanbo Song, Fabrice Branle, Michael Shi, Dong-Wan Kim
Summary: This study evaluated the efficacy and safety of the ALK inhibitor ceritinib in patients with ALK(+) NSCLC with brain metastases and/or leptomeningeal disease. The results showed that ceritinib demonstrated anti-tumor activity in these patients.
CLINICAL CANCER RESEARCH
(2022)
Review
Oncology
Ningning Yan, Sanxing Guo, Huixian Zhang, Ziheng Zhang, Shujing Shen, Xingya Li
Summary: This review summarizes the characteristics and challenges of BRAF mutations in NSCLC, as well as the treatment strategies and resistance mechanisms of BRAF-targeted therapy.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Luke McLean, Jose Luis Leal, Benjamin J. Solomon, Thomas John
Summary: The use of immune checkpoint inhibitors has changed treatment strategies for advanced non-small cell lung cancer, but most patients do not respond to monotherapy. Smokers and patients with high mutation load tumors are associated with better treatment responses.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Review
Oncology
Tania Crombet Ramos, Orestes Santos Morales, Grace K. Dy, Kalet Leon Monzon, Agustin Lage Davila
Summary: CIMAvax-EGF is a novel approach for treating NSCLC by neutralizing EGF and inhibiting tumor growth, showing potential efficacy. Clinical trials have demonstrated that CIMAvax-EGF can prolong overall survival in advanced NSCLC patients, especially those with higher EGF concentrations.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Jon Apple, Rahul Shenolikar, Kevin De Silva, Ping Sun, Alexander Spira
Summary: This study evaluated the initiation of first-line therapy in EGFRm mNSCLC patients based on biomarker testing results. The results showed that EGFR TKIs as first-line therapy had better treatment outcomes compared to IO and chemotherapy.
Article
Oncology
Takahiro Fukushima, Yoshitaka Oyamada, Shinnosuke Ikemura, Shigenari Nukaga, Takashi Inoue, Daisuke Arai, Keiko Ohgino, Aoi Kuroda, Kota Ishioka, Fumio Sakamaki, Yusuke Suzuki, Hideki Terai, Hiroyuki Yasuda, Ichiro Kawada, Koichi Fukunaga, Kenzo Soejima
Summary: This study aimed to investigate the treatment of advanced NSCLCs in patients aged 80 and over and identify therapies that can improve their prognosis. Biomarker-matched therapy was found to be effective, while the effectiveness of chemotherapy for biomarker-negative/unknown patients was questionable.
CLINICAL LUNG CANCER
(2022)
Review
Oncology
Sagun Parakh, Matthias Ernst, Ashleigh R. Poh
Summary: Persistent activation of STAT3 in non-small cell lung cancer is associated with poor prognosis, making it a potential therapeutic target. Understanding the molecular and immunological mechanisms of STAT3 activation can provide insights into its role in NSCLC development, serving as prognostic and predictive biomarker. Current STAT3-targeting therapies in clinical trials face challenges in clinical settings.
Review
Oncology
Mariam Elshatlawy, Josephina Sampson, Katy Clarke, Richard Bayliss
Summary: Different variants of the EML4-ALK fusion gene in non-small cell lung cancer have different impacts on patient prognosis and metastatic risk. These variants form cellular compartments with distinct physical properties, which affect sensitivity to ALK tyrosine kinase inhibitors. The latest generation of ALK inhibitors is effective for most patients, but resistance can occur due to point mutations within the kinase domain of the EML4-ALK fusion.
MOLECULAR ONCOLOGY
(2023)
Review
Oncology
Leylah M. Drusbosky, Estelamari Rodriguez, Richa Dawar, Chukwuemeka V. Ikpeazu
Summary: Recent FDA approvals for tumor-agnostic drugs have shifted cancer treatment from organ/histology-specific strategies to biomarker-guided approaches. RET gene fusions, known oncogenic drivers in various tumors, can be effectively targeted by inhibitors like selpercatinib and pralsetinib, showing significant clinical benefits in NSCLC patients.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Hyoung-oh Jeong, Hayoon Lee, Hyemin Kim, Jinho Jang, Seunghoon Kim, Taejoo Hwang, David Whee-Young Choi, Hong Sook Kim, Naeun Lee, Yoo Mi Lee, Sehhoon Park, Hyun Ae Jung, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Semin Lee, Se-Hoon Lee
Summary: The study found that specific cell types such as lung epithelial precursor cells and transitional effector T cells, as well as an immunosuppressive microenvironment, were enriched in the MPE of EGFR TKI-resistant patients, potentially associated with their response to TKI therapy.
Review
Medicine, General & Internal
Marcus Skribek, Konstantinos Rounis, Georgios Tsakonas, Simon Ekman
Summary: The emergence of tyrosine kinase inhibitors and immune checkpoint inhibitors has improved survival rates for non-small cell lung cancer patients, but also presents new challenges in terms of managing the unique toxicity profiles of these drugs.
JOURNAL OF INTERNAL MEDICINE
(2022)
Article
Oncology
Yi-Bing Xu, Yiping Zhang, Zhengbo Song, Wenxian Wang, Lan Shao
Summary: Cystic brain metastasis may be more likely to occur in NSCLC patients with genetic mutations. Treatment regimens, such as targeted therapies and chemotherapy, show significant differences in PFS and OS, with targeted therapies having better outcomes for patients with cystic BM.
CANCER MANAGEMENT AND RESEARCH
(2021)